Senior Vice President of Research and Chief Scientific Officer · CRESCENT BIOPHARMA, INC. (CBIO)

John Magnani

A named executive officer of CRESCENT BIOPHARMA in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,121,337

Salary $428,410Stock awards $131,445Bonus $202,400

FY2019: $1,255,451

4th of 4 named executive officers at Crescent Biopharma by FY2021 total.

4 named officers on file for CRESCENT BIOPHARMA, FY2021

John Magnani’s pay file — $29

  • 4 fiscal years of pay, line by line
  • CBIO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRESCENT BIOPHARMA’s whole pay program stands against its peers

  • CRESCENT BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2022 (DEF 14A).

Free

Get John Magnani’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

John Magnani compensation by year

CRESCENT BIOPHARMA Summary Compensation Table · all 4 fiscal years held
In US dollars, as CRESCENT BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2021
Salary$378,000$393,000$404,800$428,410
Bonus$0$0$0$202,400
Stock awards$0$0$0$131,445
Option awards$320,250$1,007,250$696,000$186,732
Non-equity incentive$181,440$150,912$146,942$164,481
Pension and deferred compensation$0$0$0$0
All other$4,050$5,447$7,709$7,869
Total$883,740$1,556,609$1,255,451$1,121,337

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 11, 2022, accession 0001558370-22-005265, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CRESCENT BIOPHARMA, INC. filed document, accession 0001558370-22-005265. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2022.

$884K
$1.6M
$1.3M
$1.1M
FY17
FY18
FY19
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU34,500$49,680—
Option69,000—$3.81
Option1,562—$20.03
Option27,083—$10.59
Option62,500—$4.72

Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

CRESCENT BIOPHARMA’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Harout SemerjianPresident and Chief Executive Officer$2,876,118
Rachel KingFormer President and Chief Executive Officer$1,420,848
Brian HahnSenior Vice President and Chief Financial Officer$1,122,561
John Magnani · this pageSenior Vice President of Research and Chief Scientific Officer$1,121,337

The full CRESCENT BIOPHARMA compensation record

free company brief

This page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Magnani's compensation dossier · One-time report. No refunds.